352 related articles for article (PubMed ID: 35056328)
1. Potential Role of Colchicine in Combating COVID-19 Cytokine Storm and Its Ability to Inhibit Protease Enzyme of SARS-CoV-2 as Conferred by Molecular Docking Analysis.
Kamel NA; Ismail NSM; Yahia IS; Aboshanab KM
Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056328
[TBL] [Abstract][Full Text] [Related]
2. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
3. Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.
Choudhary S; Nehul S; Singh A; Panda PK; Kumar P; Sharma GK; Tomar S
IUBMB Life; 2024 May; 76(5):228-241. PubMed ID: 38059400
[TBL] [Abstract][Full Text] [Related]
4. Effect of dihydromyricetin on SARS-CoV-2 viral replication and pulmonary inflammation and fibrosis.
Xiao T; Wei Y; Cui M; Li X; Ruan H; Zhang L; Bao J; Ren S; Gao D; Wang M; Sun R; Li M; Lin J; Li D; Yang C; Zhou H
Phytomedicine; 2021 Oct; 91():153704. PubMed ID: 34419736
[TBL] [Abstract][Full Text] [Related]
5. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
6. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
[TBL] [Abstract][Full Text] [Related]
7. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
9. Apigenin analogues as SARS-CoV-2 main protease inhibitors:
Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I
Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792
[TBL] [Abstract][Full Text] [Related]
10. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
Pathak Y; Mishra A; Choudhir G; Kumar A; Tripathi V
Pharmacol Rep; 2021 Jun; 73(3):926-938. PubMed ID: 33970450
[TBL] [Abstract][Full Text] [Related]
11. Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease.
Wei W; Kong N; Liu MZ; Han T; Xu JF; Liu C
Biochem Biophys Res Commun; 2022 Aug; 616():8-13. PubMed ID: 35636257
[TBL] [Abstract][Full Text] [Related]
12. Both Baicalein and Gallocatechin Gallate Effectively Inhibit SARS-CoV-2 Replication by Targeting M
Xiao T; Cui M; Zheng C; Zhang P; Ren S; Bao J; Gao D; Sun R; Wang M; Lin J; Zhang L; Li M; Li D; Zhou H; Yang C
Inflammation; 2022 Jun; 45(3):1076-1088. PubMed ID: 34822072
[TBL] [Abstract][Full Text] [Related]
13. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.
Vitiello A; Ferrara F
Respir Med; 2021 Mar; 178():106322. PubMed ID: 33550151
[TBL] [Abstract][Full Text] [Related]
14. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
15. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
[TBL] [Abstract][Full Text] [Related]
16. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
17. A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment.
Kumar R; Kumar V; Lee KW
Comput Biol Med; 2021 Mar; 130():104186. PubMed ID: 33360831
[TBL] [Abstract][Full Text] [Related]
18. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
[TBL] [Abstract][Full Text] [Related]
19. Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease.
Gogoi N; Chowdhury P; Goswami AK; Das A; Chetia D; Gogoi B
Mol Divers; 2021 Aug; 25(3):1745-1759. PubMed ID: 33236176
[TBL] [Abstract][Full Text] [Related]
20. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
Elzupir AO
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
